MIMEDX to Present at Upcoming Investor Conferences

Rhea-AI Summary

Marietta, Ga., Nov. 10, 2022 – MiMedx Group (Nasdaq: MDXG), a placental biologics company, announced its participation in two upcoming investor conferences. Senior management will present at the Canaccord Genuity MedTech Forum on November 17, 2022, at 9:30 AM ET, and at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, also at 9:30 AM ET. Webcasts for both events will be available on the company's website. MiMedx specializes in developing and distributing placental tissue allografts for non-healing wounds and degenerative musculoskeletal conditions.

MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the following investor conferences:

• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
  Presentation: Thursday, November 17, 2022 at 9:30 AM ET
  Webcast: Click here to access

• Piper Sandler 34^th Annual Healthcare Conference
  Presentation: Wednesday, November 30, 2022 at 9:30 AM ET
  Webcast: Click here to access

Institutional investors interested in meeting with senior management may contact their respective Canaccord Genuity or Piper Sandler representative.

A live webcast of both presentations will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What are the upcoming investor conferences for MiMedx Group (MDXG)?

MiMedx Group will present at the Canaccord Genuity MedTech Forum on November 17, 2022, and at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022.

When is the Canaccord Genuity MedTech Forum presentation for MDXG?

The Canaccord Genuity MedTech Forum presentation for MiMedx (MDXG) is scheduled for November 17, 2022, at 9:30 AM ET.

How can I access the webcasts for MiMedx Group's presentations?

Webcasts for MiMedx Group's presentations can be accessed through their website or via the links provided in the press release.

What is the focus of MiMedx Group's business?

MiMedx Group focuses on developing and distributing placental tissue allografts for patients with acute and chronic non-healing wounds and musculoskeletal conditions.

What proprietary process does MiMedx Group use for their products?

MiMedx Group employs the PURION® process for processing human placental tissues used in their allografts.